The All India Institute of Medical Sciences Delhi to start screening children whose aged between 2-18years for the clinical trials of Covaxin. Bharat Biotech and ICMR have developed the Covid-19 vaccine. AIIMS Delhi has made this decision after AIIMS Patna, which started the trials recently on children aged between 12 and 18 years.
AIIMS Delhi has started the children screening for Covaxin trials after getting permission from the Drugs Controller General of India (DCGI). The DCGI department approval also followed by a recommendation by the Subject Expert Committee (SEC) on May 12.
However, a total of 525 children included in these clinical trials of Covaxin. These children may divided into three different groups. The first group has 175 children whose age is between 12 and 18 years, the second group has 175 children aged between 6 and 12 years, and the third group has another 175 children aged between 2 and 6 years.
These children will receive two doses of the Covaxin vaccine through the intramuscular route. The second dose will be given after 28 days of the first dose.